Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2424140rdf:typepubmed:Citationlld:pubmed
pubmed-article:2424140lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:2424140lifeskim:mentionsumls-concept:C0013492lld:lifeskim
pubmed-article:2424140lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:2424140lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:2424140lifeskim:mentionsumls-concept:C0449774lld:lifeskim
pubmed-article:2424140pubmed:issue3lld:pubmed
pubmed-article:2424140pubmed:dateCreated1986-6-27lld:pubmed
pubmed-article:2424140pubmed:abstractTextThe known cross-reactivity of monoclonal antibodies prepared against CD1 and HLA-DR antigens with skin components prompted us to study the reactivity pattern of human eccrine sweat glands with a panel of monoclonal antibodies directed against CD1 antigens (OKT6, BL6, D-47) and against HLA-class II antigens (anti-DR, BL2, LEU-10, IV-D12, MAJA-7). The labelling pattern of eccrine glands with the panel of monoclonal antibodies used in this study permits to establish three different antigenic compartments on eccrine glands: 1) acrosyringium and distal part of dermal duct anti-DR+, BL2+, LEU-10+, IV-D12+; 2) proximal part of dermal duct MAJA-7+; 3) secretory part D-47+. The immunological markers used in this work provide a useful tool for investigation of eccrine gland differentiation and human eccrine glandular pathology.lld:pubmed
pubmed-article:2424140pubmed:languageenglld:pubmed
pubmed-article:2424140pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2424140pubmed:citationSubsetIMlld:pubmed
pubmed-article:2424140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2424140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2424140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2424140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2424140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2424140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2424140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2424140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2424140pubmed:statusMEDLINElld:pubmed
pubmed-article:2424140pubmed:monthMarlld:pubmed
pubmed-article:2424140pubmed:issn0001-2815lld:pubmed
pubmed-article:2424140pubmed:authorpubmed-author:CapraJ DJDlld:pubmed
pubmed-article:2424140pubmed:authorpubmed-author:ThivoletJJlld:pubmed
pubmed-article:2424140pubmed:authorpubmed-author:SchmittDDlld:pubmed
pubmed-article:2424140pubmed:authorpubmed-author:StaquetM JMJlld:pubmed
pubmed-article:2424140pubmed:authorpubmed-author:GomezDDlld:pubmed
pubmed-article:2424140pubmed:authorpubmed-author:Dezutter-Damb...lld:pubmed
pubmed-article:2424140pubmed:authorpubmed-author:KanitakisJJlld:pubmed
pubmed-article:2424140pubmed:issnTypePrintlld:pubmed
pubmed-article:2424140pubmed:volume27lld:pubmed
pubmed-article:2424140pubmed:ownerNLMlld:pubmed
pubmed-article:2424140pubmed:authorsCompleteYlld:pubmed
pubmed-article:2424140pubmed:pagination163-71lld:pubmed
pubmed-article:2424140pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:meshHeadingpubmed-meshheading:2424140-...lld:pubmed
pubmed-article:2424140pubmed:year1986lld:pubmed
pubmed-article:2424140pubmed:articleTitleReactivity pattern of anti-CD1 and anti-HLA class II monoclonal antibodies with human eccrine sweat glands.lld:pubmed
pubmed-article:2424140pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2424140pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:2424140pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed